首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Annexins A2 A6 and Fetuin-A Affect the Process of Mineralization in Vesicles Derived from Human Osteoblastic hFOB 1.19 and Osteosarcoma Saos-2 Cells
【2h】

Annexins A2 A6 and Fetuin-A Affect the Process of Mineralization in Vesicles Derived from Human Osteoblastic hFOB 1.19 and Osteosarcoma Saos-2 Cells

机译:Annexins A2A6和Fetuin-A影响源自人骨细胞HFOB 1.19和骨肉瘤SAOS-2细胞的囊泡中的矿化过程

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

The mineralization process is initiated by osteoblasts and chondrocytes during intramembranous and endochondral ossifications, respectively. Both types of cells release matrix vesicles (MVs), which accumulate Pi and Ca2+ and form apatites in their lumen. Tissue non-specific alkaline phosphatase (TNAP), a mineralization marker, is highly enriched in MVs, in which it removes inorganic pyrophosphate (PPi), an inhibitor of apatite formation. MVs then bud from the microvilli of mature osteoblasts or hypertrophic chondrocytes and, thanks to the action of the acto-myosin cortex, become released to the extracellular matrix (ECM), where they bind to collagen fibers and propagate mineral growth. In this report, we compared the mineralization ability of human fetal osteoblastic cell line (hFOB 1.19 cells) with that of osteosarcoma cell line (Saos-2 cells). Both types of cells were able to mineralize in an osteogenic medium containing ascorbic acid and beta glycerophosphate. The composition of calcium and phosphate compounds in cytoplasmic vesicles was distinct from that in extracellular vesicles (mostly MVs) released after collagenase-digestion. Apatites were identified only in MVs derived from Saos-2 cells, while MVs from hFOB 1.19 cells contained amorphous calcium phosphate complexes. In addition, AnxA6 and AnxA2 (nucleators of mineralization) increased mineralization in the sub-membrane region in strongly mineralizing Saos-2 osteosarcoma, where they co-localized with TNAP, whereas in less mineralizing hFOB 1.19 osteoblasts, AnxA6, and AnxA2 co-localizations with TNAP were less visible in the membrane. We also observed a reduction in the level of fetuin-A (FetuA), an inhibitor of mineralization in ECM, following treatment with TNAP and Ca channels inhibitors, especially in osteosarcoma cells. Moreover, a fraction of FetuA was translocated from the cytoplasm towards the plasma membrane during the stimulation of Saos-2 cells, while this displacement was less pronounced in stimulated hFOB 19 cells. In summary, osteosarcoma Saos-2 cells had a better ability to mineralize than osteoblastic hFOB 1.19 cells. The formation of apatites was observed in Saos-2 cells, while only complexes of calcium and phosphate were identified in hFOB 1.19 cells. This was also evidenced by a more pronounced accumulation of AnxA2, AnxA6, FetuA in the plasma membrane, where they were partly co-localized with TNAP in Saos-2 cells, in comparison to hFOB 1.19 cells. This suggests that both activators (AnxA2, AnxA6) and inhibitors (FetuA) of mineralization were recruited to the membrane and co-localized with TNAP to take part in the process of mineralization.
机译:分别在蛋白质和中间骨质骨化期间由成骨细胞和软骨细胞引发矿化过程。两种类型的细胞释放基质囊泡(MVS),其在其腔内积聚PI和Ca2 +并形成磷灰石。组织非特异性碱性磷酸酶(TNAP),矿化标记物高度富集在MV中,其中其除去无机焦磷酸盐(PPI),磷灰石形成的抑制剂。 MVS从成熟成骨细胞或肥厚性软骨细胞的微绒毛中芽,并且由于肌动菌菌丝蛋白皮质的作用,释放到细胞外基质(ECM)中,它们与胶原纤维结合并繁殖矿物生长。在本报告中,我们将人胎儿成骨细胞系(HFOB 1.19细胞)的矿化能力与骨肉瘤细胞系(Saos-2细胞)进行了比较。两种类型的细胞能够在含有抗坏血酸和β甘油磷酸酯的骨质发生培养基中矿化。细胞质囊泡中的钙和磷酸盐化合物的组成不同于胶原酶消化后释放的细胞外囊泡(大部分MV)。磷灰石仅在衍生自SaOS-2细胞的MV中鉴定,而来自HFOB 1.19细胞的MV含有非晶磷酸钙络合物。此外,ANXA6和ANXA2(矿化的核心核心)在亚膜区的强烈矿化的亚斯-2骨肉瘤中增加了矿化,在那里与TNAP共同定位,而在较少的矿化HFOB 1.19骨盆,ANXA6和ANXA2共同定位中在膜上不太可见TNAP。在用TNAP和Ca通道抑制剂治疗后,我们还观察到胎儿-A(FETUA)水平,ECM中的矿化抑制剂,特别是在骨肉瘤细胞中。此外,在刺激SAOS-2细胞期间,在刺激筛选期间,将Fetua的一部分从细胞质转移到质膜,而这种位移在刺激的HFOB 19细胞中不太明显。总之,骨肉瘤SAOS-2细胞比骨质细胞HFOB 1.19细胞具有更好的矿化能力。在SAOS-2细胞中观察到磷灰石的形成,而在HFOB 1.19细胞中仅鉴定钙和磷酸盐的复合物。这也是通过血浆膜中的ANXA2,ANXA6,FETUA的更明显的积累来证明,与HFOB 1.19细胞相比,它们在SAOS-2细胞中部分地与TNAP部分共同定位。这表明促进矿化的活化剂(ANXA2,ANXA6)和抑制剂(FETUA)被募集到膜上,并与TNAP共同定位,参与矿化过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号